Nanotechnology is quickly changing how we approach drug delivery, offering unprecedented possibilities for targeted, efficient, and precise therapeutic intervention. With continuous healthcare demands and complex diseases coupled with limited treatments, the need for nanotechnology in drug delivery systems (NDDS) becomes increasingly indispensable. This high technology is changing the barriers of medicine and improving patient outcomes with great leaps in the treatment of some of the most urgent health issues in medicine today.
Nanotechnology Drug Delivery: A Medical Revolution
Nanotechnology in drug delivery is revolutionizing medical treatments by precisely targeting drugs to specific cells or tissues, thereby reducing side effects and improving drug bioavailability. NDDS targets diseased areas, especially in cancer, neurological disorders, and autoimmune diseases, which is unlike traditional methods of distributing drugs throughout the body. This level of specificity not only enhances the therapeutic effect but also reduces the damage to healthy tissues, making treatments far more effective and less toxic.
Recent research has shown great promise with nanoparticles-presenting the size of tiny particles that can carry drugs and release them only in the desired location, thus realizing maximum therapeutic benefit. Nanocarriers, ranging from liposomes, and dendrimers, to micelles, have emerged as the ultimate candidates for better delivery of the drug and precision. Nanoparticles can evade biological barriers like the blood-brain barrier, which previously posed the greatest challenge in treating neurological conditions.
A Global Surge in Demand for Nanotechnology Drug Delivery
The global market for nanotechnology drug delivery systems is growing rapidly. It is estimated that the market will reach more than USD 218.3 billion by 2031, as demand increases for advanced treatments in oncology, cardiovascular diseases, and neurological disorders. The aging population and chronic diseases, coupled with the personalization of medicine, are also among factors leading to the use of nanotechnology-based drug delivery solutions.
North America is projected to remain a market leader and continue to occupy the largest share of the pie due to robust healthcare infrastructure, research capabilities, and favorable regulatory environment. It is here in the United States that many companies and biotech firms are actually leading the developments and commercialization of nanomedicines.
The markets for nanotechnology drug delivery in Europe, where countries like Germany, the United Kingdom, and Switzerland have experienced an extremely rapid pace of growth, play a huge role in the overall nanomedicine landscape around the world. A lot of emphasis on research and development that is backed up by the government through various innovations has contributed to this role.
Asia-Pacific is likely to get the highest market CAGR in nanotechnology drug delivery systems, led by China, Japan, and India. In this region, there are primarily two growth drivers: affordable health care solutions compounded with the seriousness of research and development put together into place by both governments and private entities. This coupled with the developing pharmaceutical industry and emerging focus of China on biotechnology has driven the country into the top ranks in the world nanomedicines market.
The Future of Nanotechnology Drug Delivery: A Bright Horizon
The future of nanotechnology in drug delivery is very promising. As research advances, we will see even more sophisticated nanoparticles designed to deliver a wide range of drugs with greater precision and efficiency. Personalized nanomedicines tailored to the genetic profiles of individual patients will revolutionize the way we treat diseases, moving away from the one-size-fits-all approach and offering more effective and safer treatments.
The other possible area in drug delivery through nanotechnology opened by AI/ML incorporation is likely to be a new frontier. AI can optimize the design of nanoparticles, simulate the behavior of drugs and how they react in the system of the body, and even suggest the most efficacious drug combinations for a personalized treatment plan. This synergy of nanotechnology and AI has the potential to change the future of medicine, allowing for more targeted, faster, and cheaper treatments for a wide range of diseases.
As the more countries are willing to invest in nanomedicine and drug delivery systems, this global market will continue to expand. Growth in precision medicine and its huge adoption in health care place a tip for the future of drug delivery to be effective, less invasive, and accessible to patients all over the world.
Recent Developments in Nanotechnology Drug Delivery
Evonik enhances its range of nanoparticle technologies and services aimed at parenteral drug delivery. (September 2023)
Evonik is enhancing its portfolio of parenteral drug delivery solutions by introducing three new standard PLA-PEG di-block copolymers, alongside a novel nanoparticle formulation service that utilizes sonication technology. The newly developed copolymers, known as RESOMER RP d, are particularly effective for the formation of nanoparticles and are applicable across a diverse array of parenteral drug delivery scenarios, including those requiring controlled and sustained release of pharmaceutical products. The innovative nanosonication process, pioneered by Evonik, addresses various production challenges and facilitates the compliant Good Manufacturing Practice (cGMP) production of nanoparticles intended for drug delivery, for which the RESOMER RP d polymers are ideally suited.
Cytiva has introduced its inaugural formulation system designed to facilitate comprehensive clinical and commercial production of lipid nanoparticle therapeutics
In July 2023, Cytiva, a prominent leader in the life sciences sector, has introduced the NanoAssemblr commercial formulation system, specifically designed for the clinical and commercial production of lipid nanoparticle therapeutics. This system is fully compliant and features automated instrumentation, enabling companies to efficiently advance these medicines to market. It utilizes a single, scalable mixing technology that supports all phases of development, ranging from research through product development to large-scale manufacturing.
Nanotechnology-based drug delivery startup Braizon Therapeutics raises ¥645 million
Braizon Therapeutics, Inc., located in Hongo, Japan, and led by Representative Director Mariko Tosu, has successfully raised 645 million yen through a third-party share allotment involving three venture capital firms, including two new investors. The company is focused on advancing groundbreaking nanotechnologies designed to overcome the blood-brain barrier, which poses a significant challenge in the treatment of central nervous system disorders, including dementia-related conditions like Alzheimer’s disease, enabling highly efficient drug delivery to the brain.
Pfizer has established a partnership with Acuitas Therapeutics to utilize a lipid nanoparticle delivery system for the development of mRNA vaccines and therapeutics
In January 2022, Pfizer Inc. and Acuitas Therapeutics, a firm specializing in lipid nanoparticle (LNP) delivery systems for messenger RNA (mRNA) therapeutics, have announced a Development and Option agreement. This agreement grants Pfizer the opportunity to non-exclusively license Acuitas’ LNP technology for up to ten targets aimed at vaccine or therapeutic development. Acuitas’ LNP technology has been clinically validated and is utilized in the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY.
NANOBIOTIX Partners With LianBio
NANOBIOTIX a biotechnology firm in the late stages of clinical development, is at the forefront of utilizing physics-based methods to enhance treatment options for cancer patients. The Company has announced that its partner, LianBio, has finalized an agreement in December 2023, with Janssen Pharmaceutica NV, a subsidiary of Johnson & Johnson. Under this agreement, LianBio has transferred its exclusive rights to develop and market the promising first-in-class radioenhancer NBTXR3 in the regions of China, South Korea, Singapore, and Thailand.
Altamira Therapeutics Reports Successful Delivery of Circular RNA Using Nanoparticle Technology
In December 2024, Altamira Therapeutics Ltd. a firm focused on advancing RNA delivery technology for applications beyond the liver, has announced the successful testing of its nanoparticle-based delivery platform for circular mRNA. In vitro studies revealed effective cell transfection and a notable increase in protein expression compared to linear mRNA, prompting the Company to file a provisional patent application with the United States Patent Office (USPTO). Altamira plans to market its platform to biotechnology and pharmaceutical companies for circular RNA applications under the CycloPhore™ brand, enhancing its existing offerings for siRNA (OligoPhore™) and mRNA (SemaPhore™).
About Author:
HTF Market Intelligence Consulting is uniquely positioned to empower and inspire with research and consulting services to empower businesses with growth strategies, by offering services with extraordinary depth and breadth of thought leadership, research, tools, events, and experience that assist in decision-making.
